Crosstalk in the Retinal Neurovascular Unit – Lessons for the Diabetic Retina

Y. Feng; S. Busch; N. Gretz; S. Hoffmann; H.-P. Hammes

doi:10.1055/s-0032-1304571

Experimental and Clinical Endocrinology & Diabetes, Inhaltsverzeichnis

Exp Clin Endocrinol Diabetes 2012; 120(04): 199-201
DOI: 10.1055/s-0032-1304571

Mini-Review Series on Diabetes and its Complications

Crosstalk in the Retinal Neurovascular Unit – Lessons for the Diabetic Retina

Authors

Y. Feng

¹Institute of Experimental and Clinical Pharmacology and Toxicology, Medical Faculty Mannheim, University of Heidelberg, Germany

²5th Medical Department, Medical Faculty Mannheim, University of Heidelberg, Germany
S. Busch

²5th Medical Department, Medical Faculty Mannheim, University of Heidelberg, Germany
N. Gretz

³Medical Research Center, Medical Faculty Mannheim, University of Heidelberg, Germany
S. Hoffmann

³Medical Research Center, Medical Faculty Mannheim, University of Heidelberg, Germany
H.-P. Hammes

²5th Medical Department, Medical Faculty Mannheim, University of Heidelberg, Germany

Abstract

Diabetic retinopathy shares important features with neurodegenerative retinal diseases, including loss of ganglion cells and retinal thinning. The impact on vasoregression and subsequent ischemia-driven changes such as macular edema and proliferative retinopathy are not established. Studies using adult neurodegenerative animal models such as the transgenic TGR(CMV-PKD2_(1/703)HA) rat imply early activation of the innate immunity system and the complement system as well as microglia playing a role in the damage of the retinal neurovascular unit.

Key words

diabetes - oxidative stress - neuropathy - reknopathy

Volltext

Referenzen

References
1 Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet 376: 124-136
2 Tang J, Kern TS. Inflammation in diabetic retinopathy. Prog Retin Eye Res 30: 343-358
3 Silva PS, Cavallerano JD, Sun JK et al. Effect of systemic medications on onset and progression of diabetic retinopathy. Nat Rev Endocrinol. 6 494–508
4 Antonetti DA, Barber AJ, Bronson SK et al. Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes 2006; 55: 2401-2411
5 Hammes HP, Federoff HJ, Brownlee M. Nerve growth factor prevents both neuroretinal programmed cell death and capillary pathology in experimental diabetes. Mol Med 1995; 1: 527-534
6 Aizu Y, Oyanagi K, Hu J et al. Degeneration of retinal neuronal processes and pigment epithelium in the early stage of the streptozotocin-diabetic rats. Neuropathology 2002; 22: 161-170
7 Barber AJ, Lieth E, Khin SA et al. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest 1998; 102: 783-791
8 Wang Q, Gorbey S, Pfister F et al. Long-term treatment with suberythropoietic Epo is vaso- and neuroprotective in experimental diabetic retinopathy. Cell Physiol Biochem 27: 769-782
9 Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54: 1615-1625
10 Du Y, Miller CM, Kern TS. Hyperglycemia increases mitochondrial superoxide in retina and retinal cells. Free Radic Biol Med 2003; 35: 1491-1499
11 Wang Y, Vom Hagen F, Pfister F et al. Receptor for advanced glycation end product expression in experimental diabetic retinopathy. Ann N Y Acad Sci 2008; 1126: 42-45
12 Hammes HP, Feng Y, Pfister F et al. Diabetic retinopathy: targeting vasoregression. Diabetes. 60 9-16
13 Pannicke T, Iandiev I, Wurm A et al. Diabetes alters osmotic swelling characteristics and membrane conductance of glial cells in rat retina. Diabetes 2006; 55: 633-639
14 Krady JK, Basu A, Allen CM et al. Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes 2005; 54: 1559-1565
15 McVicar CM, Hamilton R, Colhoun LM et al. Intervention with an erythropoietin-derived peptide protects against neuroglial and vascular degeneration during diabetic retinopathy. Diabetes 60: 2995-3005
16 Gallagher AR, Hoffmann S, Brown N et al. A truncated polycystin-2 protein causes polycystic kidney disease and retinal degeneration in transgenic rats. J Am Soc Nephrol 2006; 17: 2719-2730
17 Feng Y, Wang Y, Stock O et al. Vasoregression linked to neuronal damage in the rat with defect of polycystin-2. PLoS One 2009; 4: e7328
18 Feng Y, Wang Y, Li L et al. Gene expression profiling of vasoregression in the retina – involvement of microglial cells. PLoS One. 6 e16865
19 Hammes HP, Lin J, Wagner P et al. Angiopoietin-2 causes pericyte dropout in the normal retina: evidence for involvement in diabetic retinopathy. Diabetes 2004; 53: 1104-1110
20 Zheng L, Kern TS. Role of nitric oxide, superoxide, peroxynitrite and PARP in diabetic retinopathy. Front Biosci 2009; 14: 3974-3987
21 Li G, Tang J, Du Y et al. Beneficial effects of a novel RAGE inhibitor on early diabetic retinopathy and tactile allodynia. Mol Vis 17: 3156-3165
22 Kumar S, Zhuo L. Longitudinal in vivo imaging of retinal gliosis in a diabetic mouse model. Exp Eye Res 91: 530-536
23 Park SH, Park JW, Park SJ et al. Apoptotic death of photoreceptors in the streptozotocin-induced diabetic rat retina. Diabetologia 2003; 46: 1260-1268
24 Barber AJ, Antonetti DA, Kern TS et al. The Ins2Akita mouse as a model of early retinal complications in diabetes. Invest Ophthalmol Vis Sci 2005; 46: 2210-2218
25 Hammes HP, Lin J, Bretzel RG et al. Upregulation of the vascular endothelial growth factor/vascular endothelial growth factor receptor system in experimental background diabetic retinopathy of the rat. Diabetes 1998; 47: 401-406
26 Kubota S, Ozawa Y, Kurihara T et al. Roles of AMP-Activated Protein Kinase in Diabetes-Induced Retinal Inflammation. Invest Ophthalmol Vis Sci 52: 9142-9148
27 Gaucher D, Chiappore JA, Paques M et al. Microglial changes occur without neural cell death in diabetic retinopathy. Vision Res 2007; 47: 612-623